Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 9/20 | 1.00 |
| ▸ | IL1B | P01584 | 9/20 | 0.51 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.49 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30108655 | 1.00 | NLRP3 (1.00) | NLRP3IL1BKAT2BCHEK2ALDH1A1 | |
| SCHEMBL28963198 | 1.00 | NLRP3 (1.00) | NLRP3IL1BKAT2BCHEK2ALDH1A1 | |
| SCHEMBL28963200 | 1.00 | NLRP3 (1.00) | NLRP3IL1BKAT2BCHEK2ALDH1A1 | |
| SCHEMBL26436297 | 0.90 | NLRP3 (0.81) | NLRP3IL1BKAT2B | |
| SCHEMBL29275846 | 0.90 | NLRP3 (0.81) | NLRP3IL1B | |
| SCHEMBL30214151 | 0.90 | NLRP3 (0.81) | NLRP3IL1B | |
| SCHEMBL29276147 | 0.89 | NLRP3 (0.81) | NLRP3IL1BKAT2BCHEK2 | |
| SCHEMBL30214821 | 0.89 | NLRP3 (0.81) | NLRP3IL1BKAT2BCHEK2 | |
| SCHEMBL29275831 | 0.89 | NLRP3 (0.81) | NLRP3IL1BKAT2BCHEK2 | |
| SCHEMBL28934418 | 0.89 | NLRP3 (0.79) | NLRP3IL1BKAT2BCHEK2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240262806-A1 | INHIBITORS OF NLRP3 | PCT THERAPEUTICS, INC. (US) | 2024-08-08 | — | — | US | claimed |
| CN-118302417-A | NLRP3 inhibitors | PTC医疗公司 | 2024-07-05 | — | — | CN | claimed |
| US-20240262806-A1 | INHIBITORS OF NLRP3 | PCT THERAPEUTICS, INC. (US) | 2024-08-08 | — | — | US | disclosed |
| CN-118302417-A | NLRP3 inhibitors | PTC医疗公司 | 2024-07-05 | — | — | CN | disclosed |
| EP-4392414-A1 | INHIBITORS OF NLRP3 | PTC Therapeutics, Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| WO-2023028534-A1 | INHIBITORS OF NLRP3 | PTC THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| CN-115433163-A | NLRP3 inflammasome inhibitor and application thereof | 药捷安康(南京)科技股份有限公司 | 2022-12-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240262806-A1 | INHIBITORS OF NLRP3 | NLRP3, NOD1, NLRP1 | NLRP3 1/4885IL1B 10/4885KAT2B 4295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.